From BrainScope’s pediatric traumatic brain injury assessment device to EOS Imaging releasing new surgery planning software, here are seven medtech stories we missed this week but thought were still worth a mention. 1. BrainScope to develop pediatric traumatic brain injury assessment device BrainScope announced in a Sept. 7 press release that it will immediately start creating […]
BrainScope Company Inc.
BrainScope raises $16m for TBI assessment device
BrainScope said yesterday that it closed a $16 million funding round for the eponymous traumatic brain injury assessment device it developed. Bethesda, Md.-based BrainScope said new backer DBL Partners joined existing investors Revolution LLC, ZG Ventures, Maryland Venture Fund participated in the round, along with unnamed existing and new investors in the round. “We are delighted to […]
BrainScope touts data from trial of BrainScope One EEG-based brain index
BrainScope today touted results from a study of its EEG-based Brain Function Index, part of its BrainScope One device, which demonstrated a “significant relationship” between BFI readings and the severity of functional impairment in mild head injuries. The study was published in the Journal of Neurotrama this month, the Bethesda, Md.-based company said. The company’s BrainScope […]
BrainScope wins FDA nod for Ahead 300 TBI scanner
Brainscope said today that it won FDA 510(k) clearance for its next-gen Ahead 300 traumatic brain injury assessment device, developed through a partnership with the U.S. Defense Dept. The Bethesda, Md.-based company’s Ahead 300 is designed to provide multiple clinically relevant measures for assessing traumatic brain injury, including concussions. The new version will also be the […]
Former AcuFocus CEO Mazzo moves to head Ophthamology at Zeiss | Personnel Moves, July 28, 2016
Former AcuFocus CEO Mazzo moves to head Ophthamology at Zeiss Carl Zeiss Meditec (ETR:AFX) said this week it tapped ex-AcuFocus CEO James Mazzo as the global president of its ophthalmology business as well as managing the entire company’s U.S. sales and service center. Mazzo comes from a 3-year run as president and CEO at AcuFocus, where […]
BrainScope wrangles up new C-suite | Personnel Moves
Brainscope today announced a number of new assignments to its executive roster, assigning 4 new picks to its c-suite. The Bethesda, Ma.-based neurotech company picked up Dr. Leslie Prichep as chief scientific officer, Kerstin Schultz as president and COO, Angad Singh as chief technology officer, and promoted Laurie Silver to CFO. “These additions to our leadership team will help […]
FDA releases PMAs for September 2014 | Regulatory news for the week of November 24, 2014
Medtech approvals: FDA releases September 2014 PMAs
November 19, 2014 by MassDevice
The U.S. Food & Drug Administration releases a list of pre-market approvals granted in September 2014. Read more
BrainScope wins FDA clearance for Ahead 100 brain-injury scanner
BrainScope said it won 510(k) clearance from the FDA for its Ahead 100 device, designed to detect traumatic brain injury.
Misonix gains 19% on swing to black | Wall Street Beat
Misonix (NSDQ:MSON) shares are up 19% today after the medical device company swung to black ink for its fiscal 4th quarter and full year.
Farmingdale, N.Y.-based Misonix posted profits of $366,000, or 5¢ per share, on sales of $1.7 million for the 12 months ended June 30 – for a 26.7% top-line gain that helped Misonix swing from a $3.5 million loss during its last fiscal year.
BG Medicine puts a new man in the corner office | Personnel Moves
Eric Bouvier took over the corner office at BG Medicine (NSDQ:BGMD) yesterday as president & CEO of the Waltham, Mass.-based diagnostics developer.
Prior to joining BG, Bouvier, 51, headed the Immunoassay business at global diagnostics company BioMérieux. He also held the role of president & CEO of BioMérieux’s U.S. subsidiary bioMerieux Inc.
InVivo readies $10M round | Funding Roundup
Spinal injury therapy maker InVivo Therapeutics Holdings Corp. (OTC:NVIV) is preparing a $10 million offering, SEC filings show.
Details haven’t yet been made public regarding pricing, but the company expects to use the proceeds for research & development, working capital, capital expenditures and other general corporate purposes.
